Jonathan Etter, MD
Ophthalmology · Miami, FLNPI 1508033432
Payments from drug & device makers
Across 247 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- AbbVie$885
- Novartis$532
- Alcon$498
- NEW World Medical,inc.$326
- Oyster Point Pharma, Inc.$310
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,93698%
- Education$801%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 26 | $1,014 |
| AbbVie(2 entities) | 43 | $885 |
| Novartis | 28 | $532 |
| Alcon | 23 | $498 |
| NEW World Medical,inc. | 4 | $326 |
| Oyster Point Pharma, Inc. | 17 | $310 |
| Ocular Therapeutix, Inc. | 13 | $267 |
| Mallinckrodt Hospital Products Inc. | 11 | $257 |
| Sun Pharmaceutical Industries Inc. | 12 | $253 |
| Bausch & Lomb Americas Inc. | 12 | $224 |
| Ivantis, Inc | 1 | $184 |
| Sight Sciences, Inc. | 5 | $178 |
| Harrow Eye, LLC | 7 | $173 |
| Tarsus Pharmaceuticals, Inc. | 5 | $165 |
| Rxsight Inc | 5 | $154 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $75 |
| Dompe US, Inc. | 3 | $72 |
| Johnson & Johnson Vision Care, Inc. | 4 | $62 |
| Thea Pharma Inc. | 3 | $58 |
| Eyepoint US, Inc. | 3 | $58 |
| Alcon Research LLC | 3 | $54 |
| Amgen | 2 | $42 |
| Aerie Pharmaceuticals, Inc. | 2 | $39 |
| Omeros Corporation | 2 | $36 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $30 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Avedro Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,061 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 133 | $194,875 |
| Cyclosporine | 60 | $34,789 |
| XiidraLifitegrast | 21 | $31,176 |
| MieboPerfluorohexyloctane/Pf | 36 | $30,960 |
| LumiganBimatoprost | 31 | $16,848 |
| Prednisolone Acetate | 211 | $11,430 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $9,781 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $5,897 |
| Latanoprost | 387 | $5,673 |
| Loteprednol Etabonate | 25 | $4,758 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,330 |
| Travoprost | 25 | $3,514 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 113 | $2,057 |
| ValacyclovirValacyclovir Hcl | 27 | $1,455 |
| Timolol Maleate | 63 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $885 | $217,621176 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $224 | $62,13557 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $39 | $9,78111 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $75 | $4,75825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.